Use of recombinant factor VIIa as a rescue treatment for intractable bleeding following repeat aortic arch repair.
Hemorrhage, refractory to aggressive conventional therapy, at a rate of 16 L/hr following separation from cardiopulmonary bypass for aortic arch repair, was controlled with a dose of 90 microg/kg of recombinant factor VIIa, repeated once after 2 hours.
Stratmann
Greg
G
Department of Anesthesia and Perioperative Care, University of California at San Francisco, San Francisco, California 94143, USA. gstratmann@anesthesia.ucsf.edu
Russell
Isobel A
IA
Merrick
Scott H
SH
D001013:Aorta, Thoracic / Q000601:surgery*; D017545:Aortic Aneurysm, Thoracic / Q000601:surgery; D001021:Aortic Valve / Q000601:surgery; D016063:Blood Loss, Surgical; D001803:Blood Transfusion; D002315:Cardiopulmonary Bypass; D005167:Factor VII / Q000627:therapeutic use*; D015942:Factor VIIa; D006488:Hemostasis, Surgical; D006490:Hemostatics / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D019106:Postoperative Hemorrhage / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D012086:Reoperation
D006490:Hemostatics; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa